中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.011 seconds)

    NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR
    1.
    发明申请
    NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR 有权
    新型血小板分子及其过程

    公开(公告)号：US20100015123A1

    公开(公告)日：2010-01-21

    申请号：US12300150

    申请日：2007-05-11

    Applicant: Krishna Murthy Ella ,  Kandaswamy Sumathy

    Inventor： Krishna Murthy Ella ,  Kandaswamy Sumathy

    IPC: A61K38/48 ,  C12N9/72 ,  C12N9/70 ,  C12P19/34 ,  C12N15/00 ,  C12P21/02

    CPC classification number: C07K14/31 ,  C07K2319/035

    Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

    Abstract translation: 新的血栓溶解蛋白分子例如重组葡激酶或链激酶，尿激酶，组织纤溶酶原激活剂等及其合适的变体，用于通过融合或通过合成候选溶栓分子与脑组织或任何其他组织靶向， 包含含有蛋白质转导结构域的强两亲性α螺旋的蛋白质序列。 用蛋白质转导结构域进行工程化的溶血蛋白分子可用于增强这些蛋白质溶解分子在细胞膜和组织（包括血脑屏障）中的摄取，并用于治疗血管性血栓形成，包括脑血管障碍 由脑血栓形成或脑出血引起的，当用作治疗剂时。 克隆，表达，纯化和蛋白质转导这些蛋白质跨细胞膜的设计和过程。

    Chimeric fusion proteins
    2.
    发明授权
    Chimeric fusion proteins 有权
    嵌合融合蛋白

    公开(公告)号：US08968728B2

    公开(公告)日：2015-03-03

    申请号：US12300150

    申请日：2007-05-11

    Applicant: Krishna Murthy Ella ,  Kandaswamy Sumathy

    Inventor： Krishna Murthy Ella ,  Kandaswamy Sumathy

    IPC: A61K38/48 ,  C12N9/72 ,  C12N9/70 ,  C12P21/04 ,  C07H21/04 ,  C07K1/00 ,  C07K14/31

    CPC classification number: C07K14/31 ,  C07K2319/035

    Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

    Abstract translation: 新的血栓溶解蛋白分子例如重组葡激酶或链激酶，尿激酶，组织纤溶酶原激活剂等及其合适的变体，用于通过融合或通过合成候选溶栓分子与脑组织或任何其他组织靶向， 包含含有蛋白质转导结构域的强两亲性α螺旋的蛋白质序列。 用蛋白质转导结构域进行工程化的溶血蛋白分子可用于增强这些蛋白质溶解分子在细胞膜和组织（包括血脑屏障）中的摄取，并用于治疗血管性血栓形成，包括脑血管障碍 由脑血栓形成或脑出血引起的，当用作治疗剂时。 克隆，表达，纯化和蛋白质转导这些蛋白质跨细胞膜的设计和过程。

    Vaccine for chikungunya virus infection
    4.
    发明授权
    Vaccine for chikungunya virus infection 有权
    基孔肯雅病毒感染疫苗

    公开(公告)号：US08865184B2

    公开(公告)日：2014-10-21

    申请号：US12439509

    申请日：2007-08-31

    Applicant: Murthy Krishna Ella ,  Kandaswamy Sumathy ,  Jaya Sheela Pydigummala ,  Nagendra R. Hegde

    Inventor： Murthy Krishna Ella ,  Kandaswamy Sumathy ,  Jaya Sheela Pydigummala ,  Nagendra R. Hegde

    IPC: A61K39/12 ,  A61K39/00 ,  C12P1/00 ,  C12N5/00 ,  C07K14/005 ,  C12N7/00

    CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/5252 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36151 ,  C12N2770/36163 ,  Y02A50/383

    Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.

    Abstract translation: 本发明涉及能够在人和其他哺乳动物宿主中引起对基孔肯雅病毒感染的保护性免疫应答的疫苗制剂。 免疫原性制剂包含稳定制剂中纯化的灭活的基孔肯雅病毒。 讨论了病毒繁殖和纯化的方法。 灭活的病毒制剂是非传染性的，免疫原性的并且在哺乳动物宿主中引发保护性免疫应答。 免疫原性组合物被配制用于体内给予人。 本发明还讨论了使用重组病毒蛋白作为免疫的抗原开发亚单位疫苗的策略。 潜在免疫原性的重组病毒抗原可用于诊断病毒的存在。

Patent Agency Ranking